Boerekamps, Anne; Vanwolleghem, Thomas; van der Valk, Marc; van den Berk, Guido E.; van Kasteren, Marjo; Posthouwer, Dirk; Dofferhoff, Anthonius S. M.; van Hoek, Bart; Ramsoekh, Dewkoemar; Koopsen, Jelle; Schinkel, Janke; Florence, Eric; Arends, Joop E.; Rijnders, Bart J. published the artcile< 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)>, HPLC of Formula: 58-97-9, the main research area is review HIV HCV genotype sofosbuvir ledipasvir.
A review. This study evaluated the effectiveness of 8 wk sofosbuvir/ledipasvir (SOF/LDV) for genotype 4 HCV-infected DAA-naive HIV-pos. and neg. patients without cirrhosis. The primary outcome was SVR in the on-treatment study population, defined as an HCV RNA below the limit of detection 12 wk after the end of therapy in all patients that had completed the 8-wk treatment course of therapy and had an HCV RNA measurement ≥12 wk after the end of therapy. The study showed that 8 wk of SOF/LDV could be an effective therapy for non-cirrhotic HCV genotype 4 infected patients with an HCV RNA load ≤10 million IU/mL and is the first to evaluate the efficacy of 8 wk of SOF/LDV in a substantial number of HIV-coinfected patients.
Journal of Hepatology published new progress about Antiviral agents (Direct-acting). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem